anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In 2019, the ARRIVE trial was published, demonstrating that in low risk nulliparous women, induction of labor at 39 weeks was associated with a decreased risk for hypertensive disorders of pregnancy and decreased risk for cesarean without any increased risk for severe neonatal complications or perinatal death. (1) Based on the results of this trial, hospitals have been questioning the feasibility of implementing a protocol which offers induction of labor to low risk women at ≥39 weeks. There are concerns regarding the ability of a busy labor and delivery to accommodate women presenting for inductions with an unfavorable cervix. Outpatient mechanical cervical ripening would allow for women to start the process of induction of labor at home. This is appealing because cervical ripening is typically the longest component of the induction process. Mechanical cervical ripening is the process by which balloons or dilators are placed into the cervix.

There is lack of evidence on Dilapan-S® as an outpatient method of cervical ripening despite the potential benefits of increased maternal satisfaction and decreased length of hospital stay. With this in mind we propose a preliminary study of 40 women to assess for feasibility of performing a large randomized control trial and assess safety with outpatient treatment. This initial study is intended to assess the feasibility of outpatient cervical ripening, next day induction of labor, and safety. After completion of this feasibility study, the investigators plan to initiate a randomized control trial to assess the efficacy of outpatient Dilapan-S® for mechanical cervical ripening.
The present invention relates to a hybrid treatment of a tumor/cancer, said treatment comprises (i) targeting the resolution of transcription-replication conflicts in a tumor/cancer; or (ii) inducing in a tumor/cancer; and the use/administration of an immune cell, or a progenitor cell thereof, which is resistant against/less susceptible to said targeting/inducing. The immune cell, or progenitor cell thereof, is envisaged to target a/said (cell(s) of) a/said (solid) tumor/cancer. The present invention further relates to a respective immune cell, or a progenitor cell thereof. The present invention further relates to a pharmaceutical composition comprising the immune cell and/or a progenitor cell thereof and to a pharmaceutical composition, a kit or a combination (e.g. set of two/three components) comprising the immune cell and/or a progenitor cell thereof and a DDIA. The present invention further relates to methods of screening for a target of a DDIA which is resistant against/less susceptible to said DDIA or for an agent that is capable of inhibiting a target in a cell of a cancer/tumor and thereby inducing DNA damage and/or preventing resolution of DNA damage in said cell of a cancer/tumor; and that is incapable of inhibiting said target which is resistant against/less susceptible to said agent in an immune cell, or progenitor cell thereof, and thereby not inducing DNA damage and/or not preventing resolution of DNA damage in said immune cell or progenitor cell thereof.
A mechanism is provided in a data processing system to implement a healthcare cognitive system which operates for predicting engagement items for care providers. An engagement item prediction component executing within the healthcare cognitive system detects a scheduled appointment between a patient and a doctor. The engagement item prediction component scans communication pattern and details of patient communications for indicators of a medical condition of the patient. The healthcare cognitive system generates a set of one or more questions related to the medical condition. The engagement item prediction component presents the set of one or more questions to the user and receives one or more responses to the set of one or more questions from the patient. The healthcare cognitive system generates one or more seed topics based on the one or more responses and presents the one or more seed topics to the doctor for the scheduled appointment.
BACKGROUND: Surgical treatment for hinge failure in mega-prosthesis continues to be a challenge. This study introduces a new method for treating hinge failure by using a unilateral prosthesis and hinge revision.
CASE PRESENTATION: We here present two patients who underwent mega-prosthesis reconstruction after resection of osteosarcoma in the distal femur. To address the issue of knee hyperextension after mega-prosthesis reconstruction, one patient underwent three revision surgeries, two surgeries were performed using the original hinge, and one surgery involved a newly designed hinge. To resolve the problem of dislocation, one patient underwent three revisions, with the first two revisions not involving hinge replacement and the third revision involving a newly designed hinge. Two replacements of unilateral prosthesis and hinge renovations were successful.
CONCLUSIONS: Unilateral prosthesis and newly designed hinge device revision are effective in treating the failure of old-fashioned mega-prosthesis hinges.
Dosage strengths of BELBUCA are based on the active moiety, buprenorphine.

The 75 mcg dosage form is a buccal film that contains 75 mcg buprenorphine. The film is white on one side, with E0 printed in black, and yellow on the other side.

The 150 mcg dosage form is a buccal film that contains 150 mcg buprenorphine. The film is white on one side, with E1 printed in black, and yellow on the other side.

The 300 mcg dosage form is a buccal film that contains 300 mcg buprenorphine. The film is white on one side, with E3 printed in black, and yellow on the other side.

The 450 mcg dosage form is a buccal film that contains 450 mcg buprenorphine. The film is white on one side, with E4 printed in black, and yellow on the other side.

The 600 mcg dosage form is a buccal film that contains 600 mcg buprenorphine. The film is white on one side, with E6 printed in black, and yellow on the other side.

The 750 mcg dosage form is a buccal film that contains 750 mcg buprenorphine. The film is white on one side, with E7 printed in black, and yellow on the other side.

The 900 mcg dosage form is a buccal film that contains 900 mcg buprenorphine. The film is white on one side, with E9 printed in black, and yellow on the other side.
INTRODUCTION AND OBJECTIVES: The management of atrial fibrillation is complex and requires improvement at strategic points, such as in the control of patients treated with vitamin K antagonists. The aim of this study was to evaluate the impact on health outcomes of a nonvalvular atrial fibrillation decision support tool based on visualization of the time in therapeutic range in primary care.
METHODS: The present randomized clinical trial was conducted in 2018 with a 1-year follow-up in 325 primary care centers in Catalonia. In the intervention centers, the decision support tool was installed to control the time in therapeutic range of patients treated with vitamin K antagonists. The tool was not visualized in the control group.
RESULTS: In total, 44 556 patients were studied. The intervention protected against admission for stroke (adjusted odds ratio [OR], 0.70; 95% confidence interval [95%CI], 0.55-0.88). The number needed to treat was 3502 (95%CI, 3305-3725) while the number of admissions for stroke avoided was 12.63 (95%CI, 11.88-13.38). The intervention also protected against mortality (adjusted OR, 0.78; 95%CI, 0.67-0.90), with a number needed to treat of 13 687 (95%CI, 10 789-18 714) and number of deaths avoided of 3.23 (95%CI, 2.36-4.10).
CONCLUSIONS: The decision support tool was associated with slight reductions in the numbers of admissions for ischemic stroke and mortality. Although the follow-up time was short and the effect of the intervention was small, the results are valuable and could improve implementation of the tool. This clinical trial was registered with ClinicalTrials.gov (NCT03367325).
PURPOSE: To provide a diagnostic compsn. which intensifies the localization of related marker specific antibodies or antibody fragments subjected to labeling to be used for the position measurement of a tumor or infectious tissue lesion and decreases the labeled antibodies and antibody fragments which are not targeted and keep circulating. CONSTITUTION: This compsn. consists of a first parenteral soln. consisting essentially of the first marker specific antibodies or antibody fragments labeled by a label, such as radioisotope, noninvasibly detectable from outside and the second parenteral soln. consisting essentially of the second unlabeled antibodies or antibody fragments specific to the first marker specific antibodies or antibody fragments. The labeled antibodies or antibody fragments are taken into the tumor or lesion tissues by the medication of the first parenteral soln. and thereafter, these tissues are medicated with the second parenteral soln. and thereafter, the tissues are scanned.
At present, investigators have a very limited view on the long-term pulmonary sequelae after COVID-19 pneumonia, particularly in the most severe forms requiring hospitalization. Early thoracic HRCT is a useful tool for the evaluation of patients suspected of COVID-19 pneumonia. Typical features are evocative of the disease in an epidemic context, with multifocal ground-glass opacities, being nodular or not, or crazy-paving with or without consolidations, with a bilateral, peripheral or mixed distribution and involvement of the posterior zones. CT manifestations of fibrosis or fibrous stripes are described in COVID-19. Pan et al observed fibrous stripes in 17% patients in the early phase of the disease. Ye et al observed bronchiectasis in 2 patients (15.4%) and evidence of pulmonary fibrosis in 3 patients (23.7%) at HRCT performed at 4 weeks. Long term data are still lacking in patients with COVID-19 and the investigators do not know how many patients will have fibrotic sequelae from the acute illness.
With the rising rates of STIs among gbMSM populations in Canada, there is an urgent need for novel interventions to prevent significant sequelae (e.g. neurosyphilis) and onward transmission of untreated infections. Despite longstanding public health efforts to encourage conventional strategies of STI prevention, gbMSM continue to bear the burden of syphilis which poses synergistic effects in the transmission of HIV. This study will add to this field through providing the first methodologically rigorous, prospective multicentre, open-label randomized controlled trial (RCT) of doxycycline-based STI PrEP (daily 100mg doxycycline) versus STI PEP (200mg doxycycline after exposure event) for the prevention of bacterial STIs among gbMSM over 15 months (60 weeks) of follow-up with adequate power to address drug efficacy in the prevention of bacterial STIs. Beyond the determination of efficacy, our trial will provide insight to the unique challenges of medication adherence through assessing the acceptability, tolerability and safety of therapy with doxycycline. This study aims to provide health care providers one additional tool to address the burden of STIs in populations with an increased likelihood of infection.
PROBLEM TO BE SOLVED: To obtain a compound useful as an antitumor agent, producible from a natural product such as Japanese Taxus cuspidata and also capable of being produced by tissue culture, which uses an easily induced callus. SOLUTION: Japanese Taxus cuspidata (e.g. grown in Miyagi prefecture or in Toyama prefecture) is used as a raw material. For instance, its leaves, core portions and barks are directly extracted with an alcohol such as methanol, several times, and the extract is condensed by an active carbon-celite treatment, etc. The condensate is further extracted with ethyl acetate. The ethyl acetate layer is extracted with a sodium bicarbonate water to obtain a carboxylic acid fraction, extracted with a dilute alkali to obtain a phenol fraction and extracted with a dilute hydrochloric acid to obtain an alkaloid fraction and a neutral fraction. The neutral fraction is charged on a silica gel chromatography column having an activated carbon layer on its top and eluted with an organic solvent to obtain taxol.
Heat-shock protein 90 (Hsp90) plays a crucial role in tumorigenesis and tumor progression; however, its mechanism of action in gastric cancer (GC) remains unclear. Here, the role of Hsp90 in GC metabolism is the focus of this research. High expression of Hsp90 in GC tissues can interact with glycolysis, collectively affecting prognosis in clinical samples. Both in vitro and in vivo experiments demonstrate that Hsp90 is able to regulate the migration and stemness properties of GC cells. Metabolic phenotype analyses indicate that Hsp90 influences glycolytic metabolism. Mechanistically, Hsp90 interacts with glycolysis-related enzymes, forming multienzyme complexes to enhance glycolysis efficiency and yield. Additionally, Hsp90 binds to cytoskeleton-related proteins, regulating the regional distribution of glycolytic enzymes at the cell margin and lamellar pseudopods. This effect could lead to a local increase in efficient energy supply from glycolysis, further promoting epithelial-mesenchymal transition (EMT) and metastasis. In summary, Hsp90, through its interaction with metabolic enzymes related to glycolysis, forms multi-enzyme complexes and regulates regional distribution of glycolysis by dynamic cytoskeletal adjustments, thereby promoting the migration and stemness of GC cells. These conclusions also support the potential for a combined targeted approach involving Hsp90, glycolysis, and the cytoskeleton in clinical therapy.
A boy in his mid-teens presented with progressively increasing bleeding from the right eye and nostril intermittently over a period of 6 weeks. A complete ophthalmic examination revealed nothing significant. His otorhinological examination and haematological investigations were within normal limits. The patient came a month later with frank bleeding from the right eye. Ophthalmic examination revealed hyperaemia and maceration of the right lower palpebral conjunctiva. A histopathological examination of conjunctival scrapings from the site showed abnormal dilated blood vessels suggestive of a vascular malformation. Digital subtraction angiography confirmed the presence of a conjunctival micro arteriovenous malformation supplied by the external carotid and ophthalmic artery branches. He underwent successful transarterial Onyx embolisation resulting in complete resolution of the haemolacria.
Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
Exemplary embodiments of the present disclosure are directed towards an artificial intelligence platform and computer implemented method for collaborating, automating and organizing drugs/medical/consultations/health information & Services between stakeholders in the pharmaceutical/healthcare industries. This also extends to professionals in the veterinary space such as veterinarians and animal specialists. The medical information generation module comprising: prescription fulfillment module, collaboration module, health assistant module, analytics module, virtual pharmacy & consultation module, and prescription auction module. The prescription fulfillment module is configured to use medical information collected from a database and, with the use of artificial intelligence, display medical information data and additional supplements & services suggestions on computing devices based on users. The collaboration module is configured to collaborate users with each other and streamline medical communication. It can be configured to generate real time alerts to proper users on the computing devices and also leverage video conferencing from the video consultation function.
Topical compositions for reducing the pigmentation of the skin comprise a cosmetically acceptable topical carrier together with 0.1-30% by weight of a C2-C6 aliphatic hydrocarbon substituted on one carbon by an -SH or -SCOR group, wherein R is alkyl having up to 6 carbons, and on a different carbon by an -NR\svR\yF group, wherein either (i) R\sv + R\yF together with the nitrogen form part of heterocycle; or (ii) R\sv is alkyl having up to 6 carbons and R\yF is H or an alkyl group having up to 6 carbons; or (iii) providing that the active agent is present only as the acid addition salt, or the composition has a pH below 6.0 and/or contains an anti-oxidant, R\sv and R\yF may each be H or an alkyl group having up to 6 carbons.  The preferred depigmenting agents are 2-mercapto-ethylamine, and N,N-dimethyl-2-mercapto-ethylamine.  The aliphatic residue may be saturated or unsaturated or cyclised (e.g. from ethane, n-butane or iso-butane, or the corresponding alkenes or cyclo-alkanes). The sulphydryl group is preferably on a primary carbon atom.  When R\sv and R\yF form part of a heterocycle group, such groups may be morpholino, pyrrolidino or piperidino.  The compositions may take the form of hydrophilic or hydrophobic ointments, creams, or aqueous, non-aqueous or emulsified lotions, and may include active ingredients such as exfoliating agents, and other depigmenting agents (e.g. catechol).  The preferred pH is 3.9 to 4.1; preferred anti-oxidants are the methyl or propyl esters of p-hydroxy-benzoic acid.  The acid addition salt of the active agent may be the hydrochloride.
The endoplasmic reticulum (ER) plays an important role in protein synthesis and its disruption can cause protein unfolding and misfolding. Accumulation of such proteins leads to ER stress, which ultimately promotes many diseases. Routine screening of ER activity in immune cells can flag serious conditions at early stages, but the current clinically used bio-probes have limitations. Herein, an ER-specific fluorophore based on a biocompatible benzothiadiazole-imine cage (BTD-cage) with excellent photophysical properties is developed. The cage outperforms commercially available ER stains in long-term live cell imaging with no fading or photobleaching over time. The cage is responsive to different levels of ER stress where its fluorescence increases accordingly. Incorporating the bio-probe into an immune disorder model, a 6-, 21-, and 48-fold increase in intensity is shown in THP-1, Raw 246.7, and Jurkat cells, respectively (within 15 min). These results strongly support that this system can be used for rapid visual and selective detection of ER stress. It is envisaged that tailoring molecular interactions and molecular recognition using supramolecular improved fluorophores can expand the library of biological probes for enhanced selectivity and targetability toward cellular organelles.
FIELD: pharmaceutical industry.SUBSTANCE: invention relates to the pharmaceutical industry and can be used in medicine or veterinary medicine to produce an organosilicon adsorbent based on a hydrogel of methyl silicic acid (polymethylsiloxane polyhydrate). The resulting sorbent can be used as an enterosorbent and detoxifying agent. A method for obtaining an adsorbent by polycondensation of 5 parts by weight of an aqueous-alkaline solution of sodium methyl silicate (density 1.20-1.30 g/cm3) with 3 parts by weight of an aqueous solution of hydrochloric acid with a concentration of 12.0-14.0, wt. %, is proposed. The components cooled to a temperature of +2° + 5°C are mixed, further maturation of the target product is carried out at room temperature from 30 to 90 minutes without stirring. The resulting hydrogel is crushed, washed by decantation with purified water and 0.3-0.8 M hydrochloric acid solution to the pH of the washing water 5.0-7.0, after which the adsorbent is dried. An adsorbent obtained by the claimed method with an adsorption activity of 6.65-7.30 mmol/g is also proposed.EFFECT: proposed method makes it possible to increase the adsorbent yield by 2%, increase the adsorption activity of the resulting adsorbent by 36% and reduce the volume of washing water 10 times, while the technology does not involve the use of ethyl alcohol and synthesis is carried out at a temperature no higher than +20°C.2 cl, 3 dwg, 3 tbl, 8 ex
The invention provides a composition for preventing prostatic hyperplasia and a preparation method thereof, relating to the technical field of traditional Chinese medicines. The composition mainly comprises the following raw materials in parts by weight: 6-10 parts of radix curcumae, 10-15 parts of sculellaria barbata, 5-7 parts of motherwort, 6-9 parts of turmeric, 2-3 parts of cricket, 4-6 parts of angelica and 3-4 parts of poria cocos. The composition takes the barbed skullcap herb, the motherwort herb and the turmeric root-tuber as main traditional Chinese medicines for activating blood and promoting urination, and has good effect of preventing liver depression and qi stagnation type prostatic hyperplasia. The prescription uses Curcuma rhizome and Gryllus chinensis as main Chinese medicinal materials for promoting blood circulation and warming yang, and has good effect in preventing prostatic hyperplasia due to insufficiency of kidney-yang. The angelica and the tuckahoe are used together to achieve the effects of tonifying qi and blood, strengthening spleen to arrest diarrhea and calming heart and tranquilizing, and the traditional Chinese medicines are assisted to further achieve the effect of activating blood, so that the Chinese medicinal composition has good effects of promoting urination and inducing diuresis, and has a good prevention effect on prostatic hyperplasia. In addition, the preparation method of the composition can improve the extraction efficiency and has higher cost performance.
The present invention relates to a polypeptide including an Fc variant produced by substituting a portion of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The present invention also relates to an antibody including the polypeptide. The Fc variant can find application in a wide range of antibodies and Fc-fusion constructs. In one aspect, the antibody or Fc fusion construct of the present invention is a therapeutic, diagnostic or laboratory reagent, preferably a therapeutic reagent. The Fc variant is suitable for use in the treatment of cancer because its in vivo half-life can be maximized by optimization of the portion of the amino acid sequence. The antibody or Fc fusion construct of the present invention is used to kill target cells that bear a target antigen, for example cancer cells. Alternatively, the antibody or Fc fusion construct of the present invention is used to block, antagonize or agonize a target antigen. For example, the antibody or Fc fusion construct of the present invention may be used to antagonize a cytokine or a cytokine receptor.